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The data presented raise a number of important ques-
tions. First of all, this study concurs with a number of
other studies that show a correlation between aneurysm
size and growth rate. In the doxycycline group, the initial
mean aneurysm diameter was 3.1 cm, whereas the AAA
diameter in the placebo group was 3.5 cm. These differ-
ences were not statistically significant because of the small
number of patients in each group and the extreme size
variability in the doxycycline-treated group. Many would
consider the aorta to be aneurysmal only after it reaches at
least 3 cm. Thus, a significant proportion of patients in the
doxycycline-treated group would not have an aneurysm by
this definition, whereas all of the aneurysms in the placebo
group were larger than 3 cm. This raises concerns that
some of these patients in the doxycycline arm of the trial
had aortic dilatation rather than a true aneurysm.
Active smoking is another potentially confounding
factor in this trial. MacSweeney et al2 have shown that
active smoking correlates well with aneurysm expansion
rates. Although the differences did not reach statistical sig-
nificance, only 18% of the patients in the doxycycline
treatment group were active smokers, whereas 53% of the
placebo group were active smokers. This increase in the
proportion of smokers combined with a larger aneurysm
size would lead to an expectation of an increased expan-
sion rate in the placebo arm of the trial independent of the
effects of doxycycline.
The overall expansion rates during the entire period of
the trial did not differ. It is not clear that the study was
originally designed for multiple interim analyses, as were
performed. The decrease in aneurysm expansion rate was
seen only after the performance of additional comparisons
at 6 to 12 months and 12 to 18 months. Thus, although
the data from this pilot trial are intriguing, an equally
appropriate conclusion of this work, considering the
absence of an effect over the entire 18-month study period,
could be that doxycycline had no effect on AAA expansion.
DOXYCYCLINE AND ABDOMINAL AORTIC
ANEURYSMS
Results from one of the first clinical trials designed to
determine whether doxycycline can inhibit the growth of
small abdominal aortic aneurysms (AAAs) are published in
this issue of the Journal of Vascular Surgery. The basis for
the trial is experimental data showing that doxycycline is a
nonspecific inhibitor of metalloproteinases and that it will
inhibit the growth of aneurysms induced in animals.1
Thirty-two of 34 eligible patients were randomized to
receive doxycycline (150 mg daily) or placebo over a 3-
month period. They underwent ultrasound surveillance
during an 18-month follow-up period. This study evalu-
ated aneurysm expansion rate and Chlamydia pneumoniae
antibody titers. The authors found that aneurysm expan-
sion rates were significantly lower in the 6- to 12-month
period and the 12- to 18-month period in the patients
receiving doxycycline. They observed a higher rate of
aneurysm expansion in the patients in the placebo group
who had elevated C pneumoniae immunoglobulin G anti-
body titers. The group also found that C-reactive protein
levels, a marker of inflammation, were reduced at 6 months
in the doxycycline group compared with baseline levels. 
The authors report that the medication was well toler-
ated in all but two patients, one of whom was in the con-
trol group. The overall expansion rate during the
18-month period was 3 mm in the placebo group and 1.5
mm in the doxycycline group. This difference is not sig-
nificant. Differences only reached significance when the
groups were broken down into 6- to 12-month and 12- to
18-month time periods.
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INVITED COMMENT
Regarding “Use of doxycycline to decrease 
the growth rate of abdominal aortic aneurysms: 
A randomized, double-blind, placebo-controlled
pilot study”
B. Timothy Baxter, MD, Omaha, Neb
If the data suggest a benefit, what is the harm in treat-
ing all patients who have AAA with doxycycline? After all,
it is cheap with relatively few apparent adverse effects. The
problem is that AAA is a prevalent disease in the elderly
population. As clinicians, we are all gaining firsthand expe-
rience in the treatment of patients with antibiotic-resistant
infections. The indiscriminate use of antibiotics is, of
course, the culprit in this worldwide problem.
The data presented in this pilot trial are important in
providing an impetus for further study in larger, prospec-
tive, controlled trials. Because of the small size of the trial
and some of the issues discussed above, this study falls
short of proving that doxycycline will inhibit aneurysm
expansion. Until there is more compelling evidence avail-
able, doxycycline should only be used for treating small
AAA in carefully planned and controlled trials, which will
help to answer this important question.
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Please see related article by Dr Martti Mosorin et al on
pages 606-10.
JOURNAL OF VASCULAR SURGERY
758 Baxter October 2001
IMAGES AND REFLECTIONS
A new section in the Journal of Vascular Surgery, Images and Reflections, gives authors the opportunity 
for reflection by submitting creative writing (prose or poetry), photographs, artwork, and unique aspects of
medical history.
Submissions must be limited to one journal page. Please contact the Editor before submission.
